Veeva Systems Shows Strong Cloud Demand

Veeva's fourth-quarter earnings per share of $2.06 comfortably beat Wall Street's consensus estimate of $1.92. This performance represents an earnings surprise of over 7%. For the full fiscal year, the company's revenue reached $3.195 billion, a 16% increase year-over-year, exceeding initial guidance. The company's success is built on its two main segments: Veeva R&D and Quality Solutions, and Veeva Commercial Solutions. In the fourth quarter, subscription services for the R&D Solutions arm grew by 20.8% year-over-year to $380.76 million, while the Commercial Solutions subscriptions saw an 11.5% increase to $326.98 million. The company ended the year with a total of 1,552 customers. Looking ahead, Veeva has provided strong guidance, projecting total revenues between $855 million and $858 million for the first quarter of fiscal 2027. For the full fiscal year 2027, it anticipates revenues in the range of $3.585 billion to $3.6 billion. This positive outlook is supported by a non-GAAP operating margin that expanded to 45.0% in the recent quarter. Veeva operates within a competitive landscape that includes major players like IQVIA, Oracle, and Dassault Systèmes. A notable development is the growing influence of Salesforce, which launched its own Life Sciences Cloud following the end of its exclusive contract with Veeva in September 2025. Despite this, many analysts maintain a "Buy" or "Overweight" rating on Veeva's stock. The broader life sciences software market is experiencing significant growth, with a projected global size expected to grow from over $19 billion in 2026 to over $43 billion by 2034. This expansion is driven by the increasing adoption of cloud-based solutions and the integration of AI and machine learning in drug discovery and clinical trials. Veeva is positioning itself to capitalize on these trends by investing in industry-specific AI integrated into its core applications. The company has seen significant momentum in its clinical and quality solutions, securing a top 20 biopharma as a new enterprise standard for its RTSM (Randomized Trial Supply Management) product. Additionally, more than 125 customers, including two top 20 biopharmas, are now live on its next-generation Vault CRM. The company's stock, which has seen some volatility, trades at a discount to its historical three-year average, which some analysts see as a potential opportunity. The consensus among many analysts is that the stock is undervalued relative to its growth prospects. Veeva's management has expressed confidence in reaching a $6 billion revenue run rate target by 2030.